



Animal models

ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis

Ying Guo^{1,2} · Yuan Zhou³ · Shohei Yamatomo^{1,2} · Hui Yang^{1,2} · Peng Zhang^{1,2} · Shi Chen^{1,2} · Stephen D. Nimer^{1,2} · Zhizhuang Joe Zhao⁴ · Mingjiang Xu^{1,2} · Jie Bai^{3,5} · Feng-Chun Yang^{1,2}

Received: 25 June 2018 / Revised: 20 November 2018 / Accepted: 29 November 2018
© Springer Nature Limited 2019

To the Editor:

M yeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders. MPNs are characterized by aberrant hematopoietic proliferation of one or more hematopoietic cell lineages with increased risks of myelofibrosis (MF) progression and leukemic transformation [1]. MPNs are distinguished into three clinical entities: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) [2]. The somatic mutation of *JAK2V617F* is considered to be the most notable landmark in the diagnosis of classic Philadelphia chromosome-negative MPNs and is present in >95% of PV patients and in ~50% of ET and PMF [3, 4]. High-throughput genomic analyses of MPN patients have identified the concurrent somatic mutations of epigenetic regulators such

as *ASXL1*, *TET2*, *IDH*, *EZH2*, and *DNMT3A* co-occurring with *JAK2* mutation, which are involved in clonal evolution, disease progression, and/or poor survival in MPNs [5, 6]. *ASXL1* (additional sex combs-like 1) is a polycomb group protein that putatively functions as a chromatin modifier. *ASXL1* mutations were identified in all types of myeloid malignancies [7–11]. In all, 34.5% of *ASXL1* mutations are found in PMF patients [11]. Despite the significant impact of *ASXL1* alteration and *JAK2V617F* on the pathogenesis of MPNs, the importance of concomitant alterations of *ASXL1* and *JAK2V617F* within distinct hematopoietic compartments and disease progression remains to be elucidated.

We assessed the frequency of *ASXL1* mutations, the clinical features, and the cumulative MF-free survival in 95 PV patients with *JAK2V617F* mutations. The diagnoses were made according to the 2016 World Health Organization criteria [12]. Among the 95 PV patients, 13 patients carrying co-mutations of *ASXL1* and *JAK2V617F* had poor MF-free survival (Fig. 1a), and the proportion of *ASXL1* mutations is higher in post-PV MF (PPMF) patients (26%) than in PV patients without MF (4%) (Fig. 1b). These patients carrying co-mutations of *ASXL1* and *JAK2V617F* had decreased level of hemoglobin (Hb), increased counts of white blood cell (WBC) and platelet (PLT), palpable splenomegaly, and clonal abnormal karyotypes when compared with PV patients with *JAK2V617F* mutation only (Fig. 1c–e, Supplementary Tables S1 and S2).

To further study the impact of *Asx1l* alteration on disease progression in *JAK2V617F*-mediated MPNs and *JAK2V617F*-mutant hematopoietic stem and progenitor cell (HSC/HPC) function, we next crossed the *JAK2*^{V617F} mice with *Asx1l*^{+/-} mice and assessed hematopoietic phenotypes in vivo [13, 14]. We found that *JAK2*^{V617F};*Asx1l*^{+/-} mice had significantly shorter mean survival rate (~60%) than *JAK2*^{V617F} or *Asx1l*^{+/-} mice (Supplementary Figure S1A). To classify the hematopoietic phenotypes in *JAK2*^{V617F};*Asx1l*^{+/-} mice, we performed a series of

These authors contributed equally: Ying Guo, Yuan Zhou


Supplementary information The online version of this article (<https://doi.org/10.1038/s41375-018-0347-y>) contains supplementary material, which is available to authorized users.

✉ Jie Bai
janebai86@hotmail.com

✉ Feng-Chun Yang
fxy37@med.miami.edu

- ¹ Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA
- ² Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL, USA
- ³ State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
- ⁴ Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
- ⁵ Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin, China

Fig. 1 *ASXL1* alteration cooperates with *JAK2*^{V617F} to accelerate MPN progression in PV patients. **a** Myelofibrosis-free survival analysis of *JAK2*^{V617F} PV patients according to the *ASXL1* mutational status from a Cox regression model. *ASXL1*^{WT}: *ASXL1*^{wild-type} ($n = 82$). *ASXL1*^{MUT}: *ASXL1*^{mutated} ($n = 13$). Log-rank test was used for survival statistics. **b** Among the 95 PV patients with *JAK2*^{V617F} mutations, the proportion of *ASXL1* mutations is higher in PPMF (26%) than in PV patients without MF (4%). **c–e** PB counts of Hb, WBC, and PLT in *JAK2*^{V617F} PV patients with WT *ASXL1* or mutated *ASXL1*. * $p < 0.05$; ** $p < 0.01$



analyses including necropsy, histology, and flow cytometry on peripheral blood (PB), bone marrow (BM), and spleen. Fibrosis was assessed at each specified time points. We found that both *JAK2*^{V617F};*Asxl1*^{+/-} and *JAK2*^{V617F} mice developed progressive MPN, including PV, ET, and MF (Supplementary Figure S1B). Notably, 5 (26%) of the 19 *JAK2*^{V617F};*Asxl1*^{+/-} mice developed MF at 2–6 months of age, which was much earlier than *JAK2*^{V617F} mice (1 (6%) of the 18 mouse develop MF at 6 months of age) (Fig. 2a). Additionally, 3 (12%) of the 26 *JAK2*^{V617F};*Asxl1*^{+/-} mice, but not the littermate controls, progressed/transformed to secondary acute myeloid leukemia (Fig. 2a, Supplementary Figure S1B–C).

The average numbers of WBC, neutrophil, and PLT were significantly higher in the PB of *JAK2*^{V617F};*Asxl1*^{+/-} mice compared with the wild-type (WT) group at the age of 2–3 months. In contrast, there was no significant difference in the WBC and neutrophil counts in the *JAK2*^{V617F} mice at the age of 2–3 months, and from 4–6 months of age, the *JAK2*^{V617F} mice started to exhibit higher counts of WBC and neutrophil (Fig. 2b–d). The Hb levels in *JAK2*^{V617F};*Asxl1*^{+/-} mice with MF were the lowest among all the groups of mice at the age of 8–10 months (Supplementary Figure S2A). The *JAK2*^{V617F};*Asxl1*^{+/-} mice exhibited splenomegaly (Supplementary Figure S2B). The histologic analysis of the femur sections from *JAK2*^{V617F};*Asxl1*^{+/-} mice displayed megakaryocytic hyperplasia (Fig. 2e). Spleen sections from *JAK2*^{V617F};*Asxl1*^{+/-} mice showed a disrupted splenic architecture and prominent

megakaryocytes and myeloid precursors (Fig. 2e). Reticulin staining of femur sections revealed extensive fibrosis in the BM of *JAK2*^{V617F};*Asxl1*^{+/-} mice at the age of 3 months (Fig. 2e). Consistently, flow cytometric analysis demonstrated that *JAK2*^{V617F};*Asxl1*^{+/-} mice had a significant expansion of erythroid precursors (Ter119⁺CD71⁺) in the BM and spleen compared with the *JAK2*^{V617F} and WT groups (Supplementary Figure S2C). The PB smear of *JAK2*^{V617F};*Asxl1*^{+/-} mice contained more bluish red blood cells compared with WT PB smear, suggesting an impaired red blood cell differentiation (Supplementary Figure S2D). Interestingly, the frequency of CD41⁺CD61⁺ megakaryocytic precursors was significantly increased in the BM of *JAK2*^{V617F};*Asxl1*^{+/-} mice by flow cytometric analysis compared with WT and *JAK2*^{V617F} mice (Supplementary Figure S2E). These data demonstrate that concurrent haploinsufficiency of *Asxl1* and *JAK2*^{V617F} enhances megakaryopoiesis and increases erythroid precursors in the BM and spleen, which may accelerate MF development in vivo.

To determine the effect of *Asxl1* alteration on *JAK2*^{V617F} HSC/HPCs, we performed flow cytometric analyses and found that the frequencies of short-term (ST)-HSC and megakaryocyte/erythroid progenitor (MEP) were significantly increased in the BM of *JAK2*^{V617F};*Asxl1*^{+/-} mice compared with those in WT mice, while the frequency of multipotent hematopoietic progenitors (MPP) was significantly decreased in the BM of *JAK2*^{V617F};*Asxl1*^{+/-} mice compared with that in WT mice (Supplementary Figure S3A–B). Colony-forming unit (CFU) assays




Fig. 2 *Asxl1* alteration cooperates with *JAK2*^{V617F} to promote MF in mice. **a** Timeline of disease progression in diseased *Asxl1*^{+/-};*JAK2*^{V617F} and *JAK2*^{V617F};*Asxl1*^{+/-} mice. 5 of the 19 *JAK2*^{V617F};*Asxl1*^{+/-} mice developed MF at 2–6 months of age ($p = 0.003$, binomial test). sAML: secondary acute myeloid leukemia **b–d** PB counts showing the numbers of WBC, neutrophil, and PLT in WT, *Asxl1*^{+/-};*JAK2*^{V617F}, and *JAK2*^{V617F};*Asxl1*^{+/-} mice according to ages of mice. **e** Shown are the hematoxylin and eosin (H&E) staining of

representative femur and spleen sections and reticulin staining of femur sections from representative WT, *Asxl1*^{+/-};*JAK2*^{V617F}, and *JAK2*^{V617F};*Asxl1*^{+/-} mice at 3 months of age. **f** Spleen cells from four groups of mice (1 month old, 3 mice per genotype) were plated in methylcellulose medium supplemented with cytokines and varying concentrations of EPO or thrombopoietin (TPO). Error bars represent mean \pm standard error of the mean (s.e.m.). * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$

revealed the total colony number and replating capacity in the BM cells of $JAK2^{V617F};Asx1I^{+/-}$ mice was significantly higher compared with those in the WT group of mice (Supplementary Figure S3C–D). Furthermore, we observed the frequencies of burst-forming unit-erythroid (BFU-E), CFU-erythroid (CFU-E), and CFU-megakaryocyte (CFU-MK) colonies were significantly increased in response to a series of doses of erythropoietin (EPO) in the spleen and BM cells from $JAK2^{V617F};Asx1I^{+/-}$ mice (Fig. 2f, Supplementary Figure S3E). Notably, EPO-independent BFU-E and CFU-E formation, a hallmark feature of PV [15], were also higher in the spleen and BM cells from $JAK2^{V617F};Asx1I^{+/-}$ mice compared with other groups of mice (Fig. 2f, Supplementary Figure S3E). Thus *Asx1I* alteration cooperates with *JAK2V617F* mutation leading to biased lineage skewing, favoring erythroid and megakaryocytic differentiation.

We have reported that leukemic transformation in MDS/MPN can occur in the aged *Asx1I*^{+/-} mice (>16 month old) [14]. In the current study, we found that three $JAK2^{V617F};Asx1I^{+/-}$ mice developed myeloid leukemia at the age of 6–8 months, which is much earlier than that found in *Asx1I*^{+/-} mice. Two of the $JAK2^{V617F};Asx1I^{+/-}$ mice also had intestinal myeloid sarcoma, which were verified by histology and flow cytometric analysis (Supplementary Figure S4A–C). The moribund leukemic $JAK2^{V617F};Asx1I^{+/-}$ mice had blast cells in PB, >20% blast cells in BM, and splenomegaly (Supplementary Figure S4D–G). The histologic analyses of femur sections revealed an increase of megakaryocytes and a decrease in erythroid islands of these $JAK2^{V617F};Asx1I^{+/-}$ mice but not in any other groups of mice. The spleen sections of $JAK2^{V617F};Asx1I^{+/-}$ mice showed a disrupted architecture with an increased proportion of myeloid cells. Reticulin staining showed extensive BM fibrosis in $JAK2^{V617F};Asx1I^{+/-}$ mice (Supplementary Figure S4H). These data indicate that *Asx1I* alteration cooperates with *JAK2V617F* mutation to accelerate myeloid leukemic transformation.

In summary, PV patients with co-mutations of *ASXL1* and *JAK2V617F* had a poor MF-free survival. Likewise, *Asx1I* loss accelerates MF in *JAK2V617F*-driven MPN in mice. $JAK2^{V617F};Asx1I^{+/-}$ mice induces megakaryocytic hyperplasia and can transform to myeloid leukemia. Future studies using the *Asx1I* and $JAK2^{V617F}$ co-mutated mice to further investigate the cooperative effect between *ASXL1* mutant and *JAK2V617F* in the progression of myeloid malignancies are warranted.

Acknowledgements This work was supported by grants from the NIH (CA172408 to F-CY and MX), the Leukemia & Lymphoma Society (Specialized Center of Research grant to F-CY, MX, and SDN), and National Natural Science Foundation of China (81770128 to YZ).

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

- Campbell PJ, Green AR. The myeloproliferative disorders. *N Engl J Med*. 2006;355:2452–66.
- Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. *Cancer*. 2009;115:3842–7.
- Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. *Lancet*. 2005;365:1054–61.
- James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. *Nature*. 2005;434:1144–8.
- Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. *Nat Rev Cancer*. 2012;12:599–612.
- Brecqueville M, Rey J, Devillier R, Guille A, Gillet R, Adelaide J, et al. Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase. *Haematologica*. 2014;99:37–45.
- Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuca N, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. *Br J Haematol*. 2009;145:788–800.
- Carbuca N, Murati A, Trouplin V, Brecqueville M, Adelaide J, Rey J, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. *Leukemia*. 2009;23:2183–6.
- Boulwood J, Perry J, Pellagatti A, Fernandez-Mercado M, Fernandez-Santamaria C, Calasanz MJ, et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. *Leukemia*. 2010;24:1062–5.
- Boulwood J, Perry J, Zaman R, Fernandez-Santamaria C, Littlewood T, Kusec R, et al. High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression. *Leukemia*. 2010;24:1139–45.
- Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, Birnbaum D. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. *J Hematol Oncol*. 2012;5:12.
- Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood*. 2016;127:2391–405.
- Xing S, Wanting TH, Zhao W, Ma J, Wang S, Xu X, et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. *Blood*. 2008;111:5109–17.
- Wang J, Li Z, He Y, Pan F, Chen S, Rhodes S, et al. Loss of *Asx1I* leads to myelodysplastic syndrome-like disease in mice. *Blood*. 2014;123:541–53.
- Prchal JF, Axelrad AA. Letter: Bone-marrow responses in polycythemia vera. *N Engl J Med*. 1974;290:1382.